- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02562573
Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome
A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome
This is a Phase 2, open-label, single-arm study of the safety and tolerability of PBI-4050 800 mg daily oral administration in type 2 diabetes patients with metabolic syndrome.
A total of 12 patients will initially be enrolled for study participation. A Data Safety Monitoring Board (DSMB) will continuously review data obtained from the 12 patients. When the 12 patients have completed at least one month of study treatment, the DSMB will meet and determine whether additional patients may be enrolled or the study should be stopped. If the safety is deemed acceptable to continue with the study, the study will enroll a maximum of 36 patients.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This Phase 2 study will be performed by 1 site in Canada. The total duration of study participation for each patient is at least 18 weeks and comprises 6 study visits.
Patients who choose to participate in the extension study will be in the study for a total of up to 32 weeks.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Alberta
-
Edmonton, Alberta, Canada
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patient is 18 years of age or older.
- Patient has signed written informed consent.
- Patient has a clinical diagnosis of type 2 diabetes mellitus with a hemoglobin A1c (HbA1c) level between 7% and 10%.
- Patient has been receiving stable antidiabetic therapy (oral agents with or without basal insulin given once daily in the evening) for a minimum of 3 months before the screening visit.
- Patient is able and willing to self-monitor blood glucose level at home.
- Patient has a body mass index (BMI) of at least 27 kg/m2.
- Patient has metabolic syndrome, having at least 3 of the 5 metabolic syndrome risk factors.
Exclusion Criteria:
- Patient requires intensive insulin therapy (defined as more than basal insulin given once daily in the evening) in addition to oral hypoglycemic agents for blood glucose control.
- Patient has recent or on-going infection requiring systemic treatment with an anti-infective agent within 30 days before screening.
- Patient has had at least one episode of severe hypoglycemia in the past 12 months, defined as having a blood glucose level < 3.0 mmol/L and/or requiring third party assistance to treat hypoglycemic episode.
- Patient has evidence of significant cardiovascular disease, including myocardial infarction, unstable angina, coronary bypass surgery, percutaneous transluminal coronary angioplasty (PTCA), congestive heart failure (New York Heart Association Class III-IV), stroke, or severe ischemic disease within 3 months before screening.
- Patient has uncontrolled hypertension with BP > 150/95 mm Hg.
- Patient has a diagnosis of rheumatic or inflammatory disease, such as rheumatoid arthritis (RA), polymyalgia rheumatic (PMR), inflammatory bowel disease (IBD); or other autoimmune or inflammatory disease such as systemic lupus erythematosus (SLE) or psoriasis.
- Patient is concurrently taking and plans to routinely continue taking anti-inflammatory medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, during the study.
- Patient is currently using weight loss medications.
- Patient has significantly elevated liver enzyme levels, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 × upper limit of normal (ULN) or total bilirubin above ULN.
- Patient has a history of chronic alcohol or other substance abuse.
- Woman who is pregnant, breast-feeding, or planning a pregnancy during the course of the study.
- Woman of childbearing potential who is unwilling to use adequate birth control throughout the duration of the study.
- Patient has any condition that, in the investigator's opinion, is likely to interfere with study conduct and compliance.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: PBI4050
Four 200 mg capsules (total 800 mg) administered orally, once a day.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Number of subjects with abnormal laboratory values and/or adverse events that are related to treatment
Tidsramme: 7 months
|
7 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change from baseline on waist circumference
Tidsramme: 6 months
|
6 months
|
|
Change from baseline on biomarkers
Tidsramme: 6 months
|
% reduction and/or increase of biomarkers
|
6 months
|
Change from baseline on antidiabetic treatment
Tidsramme: 6 months
|
Treatment discontinued, dosing change, and/or new medication added
|
6 months
|
Change from baseline on triglycerides
Tidsramme: 6 months
|
6 months
|
|
Change from baseline on BP
Tidsramme: 6 months
|
6 months
|
|
Change from baseline on HDL-C
Tidsramme: 6 Months
|
6 Months
|
|
Change from baseline on fasting plasma glucose
Tidsramme: 6 months
|
6 months
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- PBI4050-ATX-9-04
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Metabolsk syndrom
-
Scripps Whittier Diabetes InstituteFullførtCardio-metabolic Care-Team Intervention (CMC-TI)
-
University of Colorado, DenverRekrutteringKlinefelters syndrom | Trisomi X | XYY syndrom | XXXY og XXXXY syndrom | Xxyy syndrom | Xyyy syndrom | Xxxx syndrom | Xxxxx syndrom | Xxxyy syndrom | Xxyyy syndrom | Xyyyy syndrom | Mann med sexkromosommosaikkForente stater
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.FullførtTidligere behandlet myelodysplastisk syndrom | Myelodysplastisk syndrom | Terapierelatert myelodysplastisk syndrom | Sekundært myelodysplastisk syndrom | Refraktært høyrisiko myelodysplastisk syndromForente stater
-
Assistance Publique - Hôpitaux de ParisRekrutteringIntensivavdelingens syndrom | Pediatrisk postintensiv syndromFrankrike
-
Hospital Universitario GetafeKarolinska Institutet; Medical University of Lodz; Universidad Politecnica... og andre samarbeidspartnereUkjentSkrøpelig eldre syndrom | Skrøpelighet | Skrøpelighet syndromPolen, Spania, Sverige
-
Shaare Zedek Medical CenterUkjentPremenstruelt syndrom - PMS
-
University of NottinghamMedical Research Council; National Institute for Health Research, United...RekrutteringSkrøpelig eldre syndrom | Skrøpelighet | Skrøpelighet syndromStorbritannia
-
Esra ÖZERKTO Karatay UniversityRekrutteringPremenstruelt syndrom - PMSTyrkia
-
Geriatric Education and Research InstituteSingapore General Hospital; Changi General Hospital; Sengkang General Hospital og andre samarbeidspartnereFullførtSkrøpelig eldre syndrom | Skrøpelighet | Skrøpelighet syndromSingapore
-
Brigham and Women's HospitalAktiv, ikke rekrutterendeSkrøpelig eldre syndrom | Skrøpelighet | Aldring | Skrøpelighet syndromForente stater
Kliniske studier på PBI4050
-
Liminal BioSciences Ltd.FullførtIdiopatisk lungefibrose (IPF)Canada